Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
3.075
+0.015 (0.49%)
Nov 21, 2024, 10:54 AM EST - Market open

Xeris Biopharma Holdings Statistics

Total Valuation

XERS has a market cap or net worth of $457.68 million. The enterprise value is $657.75 million.

Market Cap 457.68M
Enterprise Value 657.75M

Important Dates

The last earnings date was Friday, November 8, 2024, before market open.

Earnings Date Nov 8, 2024
Ex-Dividend Date n/a

Share Statistics

XERS has 149.08 million shares outstanding. The number of shares has increased by 5.01% in one year.

Current Share Class 149.08M
Shares Outstanding 149.08M
Shares Change (YoY) +5.01%
Shares Change (QoQ) +0.44%
Owned by Insiders (%) 4.42%
Owned by Institutions (%) 43.67%
Float 142.50M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 2.35
Forward PS 2.08
PB Ratio n/a
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 3.51
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.79

Current Ratio 1.79
Quick Ratio 1.21
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -1.52

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -8.70%
Return on Capital (ROIC) -11.90%
Revenue Per Employee $496,979
Profits Per Employee -$167,408
Employee Count 377
Asset Turnover 0.58
Inventory Turnover 0.84

Taxes

Income Tax -2.50M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +72.88% in the last 52 weeks. The beta is 1.28, so XERS's price volatility has been higher than the market average.

Beta (5Y) 1.28
52-Week Price Change +72.88%
50-Day Moving Average 3.03
200-Day Moving Average 2.50
Relative Strength Index (RSI) 47.67
Average Volume (20 Days) 1,959,694

Short Selling Information

The latest short interest is 11.37 million, so 7.63% of the outstanding shares have been sold short.

Short Interest 11.37M
Short Previous Month 11.57M
Short % of Shares Out 7.63%
Short % of Float 7.98%
Short Ratio (days to cover) 9.52

Income Statement

In the last 12 months, XERS had revenue of $187.36 million and -$63.11 million in losses. Loss per share was -$0.44.

Revenue 187.36M
Gross Profit 152.44M
Operating Income -45.17M
Pretax Income -59.08M
Net Income -63.11M
EBITDA -33.06M
EBIT -45.17M
Loss Per Share -$0.44
Full Income Statement

Balance Sheet

The company has $69.40 million in cash and $270.97 million in debt, giving a net cash position of -$201.56 million or -$1.35 per share.

Cash & Cash Equivalents 69.40M
Total Debt 270.97M
Net Cash -201.56M
Net Cash Per Share -$1.35
Equity (Book Value) -28.32M
Book Value Per Share -0.19
Working Capital 71.79M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$31.49 million and capital expenditures -$780,000, giving a free cash flow of -$32.27 million.

Operating Cash Flow -31.49M
Capital Expenditures -780,000
Free Cash Flow -32.27M
FCF Per Share -$0.22
Full Cash Flow Statement

Margins

Gross margin is 81.36%, with operating and profit margins of -24.11% and -33.69%.

Gross Margin 81.36%
Operating Margin -24.11%
Pretax Margin -35.02%
Profit Margin -33.69%
EBITDA Margin -17.65%
EBIT Margin -24.11%
FCF Margin -21.40%

Dividends & Yields

XERS does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -5.01%
Shareholder Yield -5.01%
Earnings Yield -13.83%
FCF Yield -7.07%

Analyst Forecast

The average price target for XERS is $4.87, which is 58.63% higher than the current price. The consensus rating is "Buy".

Price Target $4.87
Price Target Difference 58.63%
Analyst Consensus Buy
Analyst Count 3
Revenue Growth Forecast (5Y) 17.30%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

XERS has an Altman Z-Score of -1.97 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -1.97
Piotroski F-Score 2